

BIOCHEMICAL STUDIES OF SELECTED PHARMACEUTICAL INDUSTRIAL WASTEWATER COMPOUNDS ON RATS

Submitted By

Ola Ahmed Rashed Rashoud

B.Sc. Science(Biochemistry), Faculty of Science, Ain Shams University, 1999

A thesis submitted in Partial Fulfillment
Of
The Requirement for the Master Degree
In
Environmental Sciences

Department of Environmental Basic Sciences
Institute of Environmental Studies and Research
Ain Shams University

2015

APPROVAL SHEET
**BIOCHEMICAL STUDIES OF SELECTED PHARMACEUTICAL
INDUSTRIAL WASTEWATER COMPOUNDS ON RATS**

Submitted By
Ola Ahmed Rashed Rashoud

B.Sc. Science(Biochemistry), Faculty of Science, Ain Shams University, 1999

This thesis Towards a Master Degree in Environmental Sciences
Has been Approved by:

Name	Signature
1-Prof. Dr. El Sayed Mohamed El Mahdy Prof. of Biochemistry Faculty of Science Helwan University	
2-Prof. Dr. Taha Abd El Azzem Mohamed Abd El- Razek Prof. of Analytical Chemistry and Head of Department of Environmental Basic Sciences Institute of Environmental Studies and Research Ain Shams University	
3-Prof. Dr. Magdy Mahmoud Mohamed Prof. of Biochemistry Faculty of Science Ain Shams University	

2015

BIOCHEMICAL STUDIES OF SELECTED PHARMACEUTICAL INDUSTRIAL WASTEWATER COMPOUNDS ON RATS

Submitted By

Ola Ahmed Rashed Rashoud

B.Sc. Science(Biochemistry), Faculty of Science, Ain Shams University, 1999

A thesis submitted in Partial Fulfillment
Of
The Requirement for the Master Degree
In
Environmental Sciences
Department of Environmental Basic Sciences

Under The Supervision of:

1-Prof. Dr. Magdy Mahmoud Mohamed

Prof. of Biochemistry
Faculty of Science
Ain Shams University

2-Dr. Nancy magdy Hana

Prof. of Pharmaceutical Analytical Chemistry
Faculty of Pharmacy
Ain Shams University

2015

ABSTRACT

Widespread occurrence of pharmaceuticals has started to attract attention as aquatic micropollutants that might have been affecting the ecological system in trace amounts. The risks associated with their introduction into wildlife habitats are becoming an important issue for both regulators and the pharmaceutical industry, because of incomplete elimination of pharmaceuticals and their metabolites from wastewater. In this study three different classes of pharmaceuticals i.e. glucocorticosteroid (dexamethasone), analgesics (paracetamol) and stimulant (caffeine) were selected for studying their effects on environmental life. The concentration of them is determined in industrial wastewater using liquid chromatography tandem mass spectrometry (LC-MS-MS) with electrospray ionization (ESI) and each was analyzed by a single multiple reaction monitoring (MRM) transition. The concentration levels of dexamethasone, paracetamol, and caffeine in wastewater were 245 ng/ml, 7216 ng/ml and 9356 ng/ml, respectively. Oral treatments of 0.25 mg/kg b.wt, 7.5 mg/kg b.wt, 9.5 mg/kg b.wt of dexamethasone, paracetamol, and caffeine respectively was studied daily over a period of three months of treatment showed a variable influence on many biochemical and haematological parameters. Dexamethasone showed an effective increase in chronic levels of triglyceride, liver enzymes (ALT, AST, and GGT), total bilirubin, neutrophils and monocytes. Paracetamol showed highly significant increase in serum creatinine, (GGT), total protein, albumin and monocyte counts. But caffeine showed highly significant increase in creatinine, liver enzymes (ALT, GGT), total protein, albumin, total white blood cells, monocyte and eosinophil counts.

Contents

List of tables	I
List of figures	III
List of abbreviations	VI
<u>Introduction</u>	1
<u>Aim of the work</u>	2
 1-Literature Review	 3
1.1 Occurrence of pharmaceuticals in wastewater	3
1.2 Sources of pharmaceuticals in wastewater	4
1.3 Conventional or traditional sewage treatment removal.....	7
1.4 Advances in analytical and detection methods	8
1.4-(a) Sample preparation	11
1.4-(b) Liquid chromatography and mass spectrometry .	13
1.5 Environmental Risk.....	14
1.6 The selected pharmaceuticals	18
1.6.1. Dexamethasone	19
1.6.2 .Paracetamol:	25
1-6-3. Caffeine	34
 2- Materials and methods	 42
2.1- Materials:	42
2.1. 1. Water analysis	42
2.1. 1.1. Active Drug and chemicals :	42
2.1.1.2. LC/MS/MS Instrumentation.....	42
2.1.1.3. Water Sample collection & Preparation.....	42
2. 1. 1.4. Preparation of standard solutions:	42
2.1. 2. Blood analysis	43
2.1. 2.1. Animal design.....	43

2. 1 .2.2. Blood sample collection	44
2.1. 2.3. Instrumentation.....	44
2. 1.2.4. Parameters to be investigated	44
2.2- Methods:	46
2.2. 1. Water analysis	46
2.2. 1.1. Solid phase extraction :	46
2. 2 .1.2. Instrument setup and calibration curve.	47
2. 2 . 1.2.1 Standards optimization.....	47
2. 2 . 1.2.1 Instrument parameters	48
2. 2 . 1.2.1 Calibration curve	49
2.2.2. Blood analysis	50
2.2. 2.1. Determination of Glucose	50
2.2. 2.2. Determination of Lipid profile	52
2.2. 2.2.1 Determination of Cholesterol.....	52
2.2. 2.2.2 Determination of Triglycerides.....	54
2.2. 2.2.3 Determination of HDL-Cholesterol	56
2.2. 2.3. Determination of Kidney function tests	58
2.2. 2.3.1 Determination of Creatinine	58
2.2. 2.3.2 Determination of Urea	60
2.2. 2.3.3 Determination of Uric acid	61
2.2. 2.4. Determination of Liver function tests	63
2.2. 2.4.1 Determination of ALT	63
2.2. 2.4.2 Determination of AST	64
2.2. 2.4.3 Determination of GGT	66
2.2. 2.4.4 Determination of T.BIL	67
2.2.2.4.5 Determination of ALP.....	68
2.2. 2.4.6 Determination of TP.....	70

2.2.2.4.7 Determination of ALB.....	71
2.2.C. Statistical analysis.....	72
3- Results	73
4- Discussion.....	104
5- Conclusion.....	120
6- Sammary	121
7- Recommendation.....	123
8- References	125

List of Tables

Table No.	Title	Page
Table (2.1)	MRM method parameters selected in positive and negative ion mode.	47
Table (2.2)	Instrument Parameters	48
Table (3.1)	Quantitative result of four industrial wastewater samples.	73
Table (3.2)	Effect of oral administration of dexamethasone on glucose & lipid profile.	81
Table (3.3)	Effect of oral administration of dexamethasone on kidney function.	83
Table (3.4)	Effect of oral administration of Dexamethasone on Liver function.	84
Table (3.5)	Effect of oral administration of dexamethasone on HB, Blood indices and platelets	86
Table (3.6)	Effect of oral administration of dexamethasone on WBCs and differential leucocyte count.	88
Table (3.7)	Effect of oral administration of paracetamol on glucose & lipid profile.	89
Table (3.8)	Effect of oral administration of paracetamol on kidney function.	91

Table No.	Title	Page
Table (3.9)	Effect of oral administration of paracetamol on Liver function.	92
Table (3.10)	Effect of treatment of rats with paracetamol on haematological parameters	93
Table (3.11)	Effect of treatment of rats with paracetamol on WBCs and differential leucocyte count	95
Table (3.12)	Effect of Caffeine treatment on Glucose and lipid profile compared	96
Table (3.13)	Effect of Caffeine treatment on kidney function.	98
Table(3.14)	Effect of Caffeine on Liver function compared to normal control group	99
Table (3.15)	Effect of oral administration of caffeine on haematological parameters	101
Table (3.16)	Effect of oral administration of caffeine on WBCs and Differential white cell count	103

List of Figures

Figure No.	Title	Page
Figure (1.1)	Sources of pharmaceuticals in the natural aquatic environment	5
Figure (1.2)	Analytical methods applied to detect the most common pharmaceuticals in wastewater	10
Figure (1.3)	Common SPE steps	12
Figure (1.4)	The principle of the multiple reaction Monitoring (MRM) in triple quadrupole mass spectrometer	14
Figure (1.5)	Therapeutic classes detected in the environment, expressed in relative percentage.	19
Figure (1.6)	Metabolism of Acetaminophen	27
Figure (1.7)	Overview of the pharmacokinetics of caffeine in humans.	36
Figure (1.8)	Physiological actions of caffeine.	37
Figure (2.1)	The total ion chromatogram (TIC) in positive and negative ion mode for standard mixture of five pharmaceutical standards.	48
Figure (2.2)	a-e Five points calibration curve for salbutamol, PCM, caffeine, timolol and dexamethasone respectively	49
Figure (3.1)	a,b Quantitative window show PCM in Sample1	74
Figure (3.2)	a,b Quantitative window show caffeine in Sample1	75
Figure (3.3)	a,b Quantitative window show dexamethasone in Sample1	76

Figure No.	Title	Page
Figure (3.4)	MRM extracted chromatogram for three pharmaceutical standards (PCM, caffeine and dexamethasone). Only one transition shown.	77
Figure (3.5)	MRM chromatogram showed panel (A) calibrator standard compared to panel (B) four industrial wastewater samples in retention time.	78
Figure (3.6)	Total ion chromatogram and extracted ion chromatogram for wastewater sample one	79
Fig (3.7)	The Change % of glucose & lipid profile during dexamethasone treatment.	82
Fig (3.8)	The Change % of kidney functions during dexamethasone treatment.	83
Fig (3.9)	a,b The Change % of Liver functions during dexamethasone treatment.	85
Fig (3.10)	The Change % of HB, Blood indices and plateletes during dexamethasone treatment.	87
Fig (3.11)	The Change % of WBCs & differential during dexamethasone treatment.	88
Fig (3.12)	The Change % of glucose & lipid profile during paracetamol treatment.	90
Fig (3.13)	The Change % of kidney profile during paracetamol treatment	91
Fig (3.14)	The Change % of liver profile during paracetamol treatment	92

Figure No.	Title	Page
Figure (3.15)	The Change % of haematological parameters during paracetamol treatment	94
Figure (3.16)	The Change % of WBCs and differential during paracetamol treatment	95
Figure (3.17)	The Change % of Glucose and Lipid profile during caffeine treatment	97
Figure (3.18)	The Change % of Kidney function during caffeine treatment	98
Figure (3.19)	The Change % of Liver function during caffeine treatment	100
Figure (3.20)	The Change % of haematological parameters during caffeine treatment	102
Figure (3.21)	The Change % of WBCs and Differential white cell count during caffeine treatment	103

List of abbreviations

ACM	Acetaminophen
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
APAP	N-acetyl-para aminophenol
API	Atmospheric pressure ionization
APIs	Active pharmaceutical ingredients
AST	Aspartate aminotransferase
AST	Aspartate aminotransferase
COX	Cyclooxygenase
DEX	Dexamethasone
ESI	Electrospray ionization
FDA	Food and Drug Administration
GC-MS	Gas chromatography with mass spectrometry
GFR	Glomerular filtration rate
GGT	Gamma-glutamyltransferase
GSH	Glutathione
Hb	Haemoglobin
HDL	High density lipoprotein
HLB	hydrophilic lipophilic balanced

HPLC,	High performance liquid chromatography
LC-MS	Liquid chromatography coupled to mass spectrometry
LDL	Low density lipoprotein
LLE	Liquid liquid extraction
MAX	Mixed mode anion exchange
MCH	Mean corpuscular hemoglobin
MCHC	Mean corpuscular hemoglobin concentration
MCV	Mean corpuscular volume
MCX	Mixed mode cation exchange
MRM	Multiple reaction monitoring
MS2	Tandem spectrometry
M-WWTPs	Municipal wastewater treatment plants
NAPQI	N-acetyl-p-benzoquinonimine
NO	Nitrogen oxide
NSAIDs	Non-steroidal anti-inflammatory drugs
PCM	Paracetamol
PCV	Packed cell volume
PFF	Pharmaceutical formulation facilities
PhCs	Pharmaceuticals
PPCPs	Pharmaceuticals and personal care products
PPF	Pharmaceutical production facilities
P-WWTPs	Pharmaceutical manufacture wastewater treatment plants

RBC	Red blood cell
SPE	Solid phase extraction
T.BIL	Total Bilirubin
TNF-a	Tumor necrosis factor a
VLDL	Very low density lipoprotein
WBCs	White blood cells
WWTPs	Wastewater treatment plants